Globus Medical (GMED) Tops Q3 EPS by 18c

Globus Medical (NYSE: GMED) reported Q3 EPS of $0.83, $0.18 better than the analyst estimate of $0.65. Revenue for the quarter came in at $625.7 million versus the consensus estimate of $604.71 million.

GUIDANCE:

Globus Medical sees FY2024 EPS of $2.90-$3.00, versus the consensus of $2.85.

For earnings history and earnings-related data on Globus Medical (GMED) click here.

You May Also Be Interested In

• JPMorgan Downgrades Anima Holding SA (ANIM3:BZ) to Neutral
• JPMorgan Upgrades Sika AG (SIKA:SW) (SKFOF) to Neutral
• JPMorgan Upgrades Visteon (VC) to Overweight